Clinical Trials on Inflammatory Bowel Disease - IBD1 in Hungary

Total 263 results

Pharmacosmos A/S

Completed

Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease

Inflammatory Bowel Disease | Anaemia

Austria, Hungary
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Australia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Belgium, Hungary, Croatia, ...
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Serbia, South Africa, Japan, Israel, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Austria, Ireland, Czech Republic, Hungary, Denmark, Icela...
AstraZeneca

Terminated

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID)

Crohn's Disease | IBD

United States, Italy, Taiwan, Korea, Republic of, Spain, Germany, Poland, Russian Federation, Israel, Ukraine, Canada, Czechia, South Africa, United Kingdom, Hungary, India, Slovakia
Sanofi

Completed

Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study (NICE)

Ulcerative Colitis | Inflammatory Bowel Disease

Canada, Brazil, Russian Federation, Italy, Spain, Sweden, Estonia, Singapore, Belgium, Czech Republic, Argentina, Hungary, Chile, South Africa
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease

Crohn's Disease

France, Israel, Italy, Netherlands, Poland, Slovakia, Ukraine, Czech Republic, Germany, Hungary, Japan
Lycera Corp.

Completed

Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis

Ulcerative Colitis

Hungary
Mitsubishi Tanabe Pharma Corporation

Completed

Extension Study of MT-1303 in Subjects With Crohn's Disease

Crohn's Disease

Czechia, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Slovakia, Ukraine
Toray Industries, Inc

Completed

A Study of TRK-170 for the Treatment of Crohn's Disease

Crohn's Disease

Bulgaria, France, Hungary, Belgium, Czech Republic, Latvia, Netherlands, Norway, Poland, Romania, Serbia, Sweden, Ukraine
AstraZeneca

Terminated

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (Expedition)

Ulcerative Colitis | IBD

United States, Italy, Taiwan, Korea, Republic of, Germany, Spain, Russian Federation, Japan, South Africa, Hungary, Poland, Israel, Puerto Rico, Czechia, Ukraine, United Kingdom, Canada, India, Slovakia
Boehringer Ingelheim

Completed

A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

Crohn Disease

Belgium, Germany, Austria, Korea, Republic of, Netherlands, Denmark, Hungary, Spain
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis

Ulcerative Colitis

Poland, Bulgaria, Hungary
Geert D'Haens
Takeda

Completed

A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOVE-CD)

Crohn Disease

Belgium, Netherlands, Hungary
Pfizer
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease (CONNECT-IBD)

Inflammatory Bowel Diseases | Crohn's Disease | Ulcerative Colitis

France, Spain, United Kingdom, Czechia, Italy, Belgium, Germany, Netherlands, Greece, Finland, Hungary, Portugal, Slovakia
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Intestinal Fistula | Inflammatory Bowel Disease

United States, Israel, Canada, United Kingdom, Germany, Belgium, Hungary, France, Austria, Czech Republic, Netherlands, Poland
Morphic Therapeutic, Inc

Recruiting

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (EMERALD-2)

Inflammatory Bowel Diseases | Colitis, Ulcerative

United States, Germany, Korea, Republic of, Italy, Poland, Australia, Georgia, Austria, Bulgaria, Czechia, Estonia, France, Hungary, India, Israel, Latvia, Lithuania, Romania, Serbia, Slovakia, Taiwan
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) (DIVERGENCE 1)

Small Bowel Crohn's Disease

United States, Belgium, United Kingdom, Germany, Spain, Czechia, Canada, Austria, France, Hungary, Italy, Ukraine
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UNIFI)

Inflammatory Bowel Diseases | Colitis, Ulcerative

United States, Australia, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Israel, Bulgaria, Romania, Serbia, Japan, Canada, Netherlands, Korea, Republic of, New Zealand, Russian Federation, Austria, Hungary, Slovakia, D... and more
Shield Therapeutics

Completed

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

Anemia, Iron-Deficiency | Crohn's Disease | Inflammatory Bowel Disease

United States, France, Germany, Spain, Belgium, Hungary
Abivax S.A.

Active, not recruiting

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis

Belgium, Poland, Czechia, Hungary
Hoffmann-La Roche

Active, not recruiting

RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease

Crohn Disease

United States, France, Poland, Hungary, Spain
Celgene

Completed

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Poland, Ukraine, Hungary, Canada
Kyowa Kirin, Inc.

Completed

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Digestive System Diseases | Gastrointestinal Diseases | Colonic Diseases | Intestinal Diseases | Abdominal Pain | Inflammatory Bowel Diseases | Ulcerative Colitis | Colitis | Colitis, Ulcerative | Autoimmune Disease

Hungary, Russian Federation, Serbia, United States, Poland, Czechia, Romania
Provention Bio, Inc.

Completed

Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease (PRINCE)

Crohn's Disease

Austria, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
Neovacs

Completed

Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients

Crohn's Disease

Germany, Belgium, France, Romania, Bulgaria, Croatia, Czech Republic, Hungary, Netherlands
EA Pharma Co., Ltd.

Completed

A Study of E6011 in Participants With Active Crohn's Disease

Crohn's Disease

Czechia, Hungary, Japan, Poland, Russian Federation
Novo Nordisk A/S

Terminated

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Inflammation | Ulcerative Colitis

Poland, Croatia, Denmark, Bulgaria, Hungary, Ukraine, Russian Federation
Geert D'Haens
Takeda

Completed

An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis (LOVE-UC)

Colitis, Ulcerative

Netherlands, Belgium, Hungary
Celltrion

Completed

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

Crohn's Disease

France, Turkey, Czechia, Greece, Latvia, Hungary, Belarus, Israel, United States, Spain, Bulgaria, Serbia, Croatia, Italy, Germany, India, Japan, Mexico, Moldova, Republic of, Peru, Poland, Romania, Russian Federation, Slovakia, South Africa and more
Bristol-Myers Squibb

Completed

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Crohn's Disease

Poland, United States, France, Belgium, Israel, Hungary, South Africa, Puerto Rico
Hoffmann-La Roche

Terminated

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

Ulcerative Colitis

United States, Hungary, Georgia, Moldova, Republic of, Ukraine
Alfasigma S.p.A.

Completed

Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease

Crohn's Disease

Israel, Italy, Russian Federation, Poland, Germany, France, Hungary
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease (Divergence2)

Fistulizing Crohn's Disease

United States, Italy, Belgium, Austria, Canada, Hungary, United Kingdom, Germany, France
Hoffmann-La Roche

Active, not recruiting

RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease

Crohn Disease

United States, Belgium, Hungary, France, Poland, Canada, Bulgaria, Spain, Germany, Slovakia
Janssen Research & Development, LLC

Active, not recruiting

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease (UNITI Jr)

Crohn Disease

United States, Israel, Belgium, Hungary, Japan, Germany, Poland, United Kingdom, Russian Federation
Celgene

Completed

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

Crohn Disease

United States, Australia, Canada, Slovakia, Hungary
Novartis Pharmaceuticals

Terminated

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

Ulcerative Colitis

Belgium, Hungary, Switzerland, Germany, Sweden, United Kingdom
Palau Pharma S.A.

Completed

A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Belgium, Hungary, Slovakia, Spain
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Crohn Disease

United States, Belgium, Germany, Hungary, Spain, United Kingdom, Denmark, Czechia, Poland, Italy, Netherlands
Pfizer

Completed

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Crohn's Disease

Korea, Republic of, United States, Spain, Netherlands, Australia, Israel, Canada, Czechia, Japan, Germany, Hungary, Austria, Bulgaria, Greece, South Africa, Ukraine, France
VHsquared Ltd.

Completed

A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease (HarbOR)

Crohn's Disease

United States, Germany, Canada, Hungary, Poland, Serbia, United Kingdom, Netherlands, Ukraine, Austria, Norway, Slovakia, Czechia
CSL Behring

Terminated

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

Germany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom
Pfizer

Completed

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

Crohn's Disease

Netherlands, United States, Hungary, Belgium, Czech Republic, Italy, South Africa, Spain, United Kingdom, Slovakia, Poland, France
Pfizer

Completed

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Crohn's Disease

United States, Spain, Israel, Netherlands, Australia, Canada, Japan, Germany, Korea, Republic of, Hungary, Austria, Bulgaria, Czech Republic, Greece, South Africa, Ukraine, France
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Crohn Disease

United States, Belgium, Hungary, France, Canada, Spain, Australia, Germany, Poland, United Kingdom
AbbVie

Recruiting

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. (UPlift)

Crohn's Disease

Australia, France, Germany, Greece, Hungary, Japan, Canada, China, Spain
Gilead Sciences

Terminated

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

Spain, United Kingdom, United States, France, Italy, Germany, New Zealand, Australia, Poland, South Africa, Hungary, Canada, Czechia
Takeda

Completed

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

Crohn's Disease

United States, Italy, Poland, France, Belgium, Canada, Hungary, Czechia
Janssen Research & Development, LLC

Completed

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Inflammation | Crohn's Disease

Belgium, France, Israel, Hungary, Russian Federation, Poland, Canada, United States

Clinical Trials on Inflammatory Bowel Disease - IBD1 in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations